Research location
Cologne
Germany
Research activity in Cologne
GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 786 trials and 974 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Cologne
786 linked trials · page 1 of 16A Study of BMS-986528 in Participants With Refractory Rheumatoid ArthritisNCT07412704 · 2026-09-15 · 1 site observation
RECRUITING
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT07680764 · 2026-09-10 · 1 site observation
RECRUITING
Stratification and Treatment in Early Psychosis Study - ENHANCENCT06778564 · 2026-09-01 · 1 site observation
RECRUITING
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation
RECRUITING
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)NCT07625644 · 2026-08-04 · 1 site observation
RECRUITING
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusNCT07662109 · 2026-07-06 · 1 site observation
RECRUITING
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMNCT07667803 · 2026-06-29 · 2 site observations
RECRUITING
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without PembrolizumabNCT07486817 · 2026-06-04 · 1 site observation
RECRUITING
BIO|STREAM.CSP StudyNCT07393009 · 2026-05-25 · 1 site observation
RECRUITING
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 · 2026-05-11 · 2 site observations
RECRUITING
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)NCT07611110 · 2026-05-04 · 1 site observation
RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILDNCT07285655 · 2026-04-23 · 1 site observation
RECRUITING
Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support PersonsNCT07788729 · 2026-04-21 · 1 site observation
RECRUITING
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)NCT07202546 · 2026-02-11 · 1 site observation
RECRUITING
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIVNCT07392372 · 2026-02-09 · 1 site observation
RECRUITING
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886 · 2026-02-06 · 1 site observation
RECRUITING
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsNCT07195695 · 2026-01-16 · 1 site observation
RECRUITING
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22 · 1 site observation
RECRUITING
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient DisordersNCT07221851 · 2025-12-12 · 1 site observation
RECRUITING
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World SettingNCT07230691 · 2025-12-03 · 2 site observations
RECRUITING
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based TreatmentNCT07281833 · 2025-11-27 · 1 site observation
RECRUITING
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic DysfunctionNCT07188805 · 2025-11-19 · 1 site observation
RECRUITING
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsNCT07291037 · 2025-10-31 · 1 site observation
RECRUITING
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisNCT07207811 · 2025-10-02 · 1 site observation
RECRUITING
#AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.NCT06900829 · 2025-10-01 · 1 site observation
RECRUITING
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 1 site observation
RECRUITING
Impella Pump Return Study to Analyze Deposits and Biomaterial in Used PumpsNCT06765226 · 2025-09-21 · 1 site observation
RECRUITING
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)NCT06855771 · 2025-09-09 · 1 site observation
RECRUITING
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's DiseaseNCT06995573 · 2025-08-25 · 1 site observation
RECRUITING
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationNCT06952803 · 2025-08-06 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)NCT06976203 · 2025-07-21 · 1 site observation
RECRUITING
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesNCT06570798 · 2025-07-16 · 1 site observation
RECRUITING
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.NCT06916806 · 2025-05-01 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerNCT06790693 · 2025-04-09 · 1 site observation
RECRUITING
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerNCT06890598 · 2025-03-27 · 1 site observation
RECRUITING
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinNCT06677060 · 2025-03-14 · 2 site observations
RECRUITING
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceNCT06830720 · 2025-02-20 · 1 site observation
RECRUITING
FMRI-neurofeedback in Parkinson's DiseaseNCT06582355 · 2025-02-10 · 1 site observation
RECRUITING
Cyclosporine In Takotsubo SyndromeNCT05946772 · 2025-02-01 · 1 site observation
RECRUITING
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 SystemNCT06807359 · 2025-01-06 · 1 site observation
RECRUITING
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve FailureNCT06557798 · 2024-12-12 · 1 site observation
RECRUITING
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast CancerNCT06607757 · 2024-12-04 · 1 site observation
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647 · 2024-11-27 · 1 site observation
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738 · 2024-11-18 · 1 site observation
RECRUITING
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET AlterationsNCT06669117 · 2024-10-22 · 1 site observation
RECRUITING
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)NCT06780150 · 2024-09-26 · 1 site observation
RECRUITING
Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControlNCT06498349 · 2024-09-05 · 1 site observation
RECRUITING
STIMPulseControl Ancillary Speech StudyNCT06561919 · 2024-09-05 · 1 site observation
RECRUITING
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)NCT06274801 · 2024-09-03 · 1 site observation
RECRUITING
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751 · 2024-08-01 · 1 site observation
RECRUITING
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.